View Older Stories View More Recent Stories
-
BofA: We see MDT rev accelerating from new bottom-up model
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Leerink Partners Reiterates Outperform Rating on Medtronic, Inc. (MDT): acquisition an "incremental positive"
-
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT): "glad to see MDT increasingly pursue tuck-in acquisitions"
-
Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT) amid acquisition announcement
-
Piper Sandler's Key Takeaways From CRT 2026
-
Medtronic (MDT) files to offer debt
-
Medtronic receives Japan reimbursement for blood pressure device
-
Medtronic, Inc. (MDT) PT Lowered to $103 at Truist Securities
-
Mizuho Reiterates Outperform Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Lowered to $120 at Needham
-
Medtronic beats Q3 expectations with highest revenue growth in 10 quarters
-
Medtronic (MDT) Tops Q3 EPS by 2c; offers guidance
-
Medtronic preview: product launches, diabetes unit progress boost growth
-
Medtronic (MDT) June 100 calls active into quarter results
-
Medtronic receives FDA clearance for spine surgery robotic system
-
Medtronic (MDT) call put ratio 1 call to 1.4 puts into quarter results
-
Barclays Reinstates Medtronic, Inc. (MDT) at Overweight
-
Needham Upgrades Medtronic, Inc. (MDT) to Buy
-
Leerink: 'MDT remains one of our Top Picks for 2026'
-
Citi Resumes Medtronic, Inc. (MDT) at Buy, Top Pick
-
Medtronic receives Medicare access and FDA clearances for diabetes system
-
Wells Fargo Resumes Medtronic, Inc. (MDT) at Overweight, Remains Top Pick for 2026
-
CICC Starts Medtronic, Inc. (MDT) at Outperform
-
Medtronic receives FDA clearance for MiniMed Go diabetes management system
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Medtronic (MDT) call put ratio 3 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Who in MedTech could get acquired at this year's healthcare investor conference in SF? Piper answers
-
Medtronic study shows diabetes system maintained glucose targets despite missed doses
-
William Blair Upgrades Medtronic, Inc. (MDT) to Outperform
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
Piper Sandler on Medtronic, Inc. (MDT): 'RDN Survey Indicates Momentum'
-
Citi Adjusts Large Cap Recommended List, Micron (MU) Removed
-
Increasing unusual call option volume: PM MDT RCL ZSL MO OMER LUV PBR AMBA RF COPX
-
Medtronic files for IPO of diabetes unit MiniMed
-
Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
-
Nephron Upgrades Medtronic, Inc. (MDT) to Buy
-
Medtronic (MDT) Declares $0.71 Annual Dividend; 0.7% Yield
-
Medtronic's (MDT) HUGO Approval an Important, Positive Step - Stifel
-
Medtronic receives FDA clearance for Hugo robotic surgery system
-
Medtronic launches MiniMed 780G system with Abbott's Instinct sensor in US
-
Medtronic, Inc. (MDT) PT Raised to $110 at Truist Securities
-
Medtronic, Inc. (MDT) PT Raised to $102 at UBS Following Q2 Print
-
Medtronic, Inc. (MDT) PT Raised at RBC Capital on Growth Acceleration
-
Medtronic, Inc. (MDT) PT Raised to $111 at Bernstein Following 'Strong Q'
-
Medtronic, Inc. (MDT) PT Raised to Street High $125 at Mizuho
-
Medtronic, Inc. (MDT) PT Raised to $114 at Wells Fargo
-
Medtronic, Inc. (MDT) PT Raised to $120 at Leerink Partners
-
Medtronic, Inc. (MDT) PT Raised to $110 at Jefferies
-
Goldman Sachs Upgrades Medtronic, Inc. (MDT) to Neutral
